Assembling industry thought-leaders, ICI Europe distilled the latest insights and more advanced science on developing next generation immune checkpoint modulators.

Coined as miracle drugs, Opdivo and Keytruda are recently approved treatments in Europe. Coupled with the many encouraging ICIs in company pipelines, we are on the cusp of revolutionising cancer treatment.

With market approval feeling more obtainable than ever, rivalry to develop the next miracle ICI is fierce. Everyone is racing to be next to market. However, development hurdles are preventing the realisation of this next generation of checkpoint blockades.

The ICI Europe meeting helped drug developers tackle these challenges and see significant pipeline development in the next 6 months.